Brought to you by 
BMS joins Sterling, Sanofi on heart projects; agreement later revised
11 Oct 2012
Executive Summary
Kodak subsidiary Sterling Winthrop and partner Sanofi have agreed with Bristol-Myers Squibb to cooperate in developing and commercializing two promising cardiovascular compounds of Sanofi, SR-47436 (irbesartan) and clopidogrel.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS joins Sterling, Sanofi on heart projects; agreement later revised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice